Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results After Market Close on July 14, 2015

TUSTIN, Calif., July 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. PPHM PPHMP, a biopharmaceutical company focused on developing novel investigational products that help harness the body's own immune system to fight cancer, today announced that it will report financial results for the fourth quarter and fiscal year (FY) 2015 ended April 30, 2015 on July 14, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's senior management will discuss financial results for the fourth quarter ended April 30, 2015 of FY 2015 and will review recent progress of its clinical development programs.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.